ABIOMED Inc
LSE:0H7S
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
N/A
N/A
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Intrinsic Value
There is not enough data to reliably calculate the intrinsic value of 0H7S.
The Intrinsic Value is calculated as the average of DCF and Relative values:
| US |
|
Abbott Laboratories
NYSE:ABT
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
|
| US |
|
Resmed Inc
NYSE:RMD
|
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Abiomed's heavy reliance on the Impella platform for most of its revenue leaves the company vulnerable to any clinical setbacks, regulatory scrutiny, or new evidence suggesting limited patient benefits, which could sharply reduce demand.
The Impella product line remains a category leader in percutaneous heart pump technology, backed by extensive clinical data and FDA indications, making it the go-to option for high-risk cardiovascular procedures.
Revenue & Expenses Breakdown
ABIOMED Inc
Balance Sheet Decomposition
ABIOMED Inc
| Current Assets | 1.1B |
| Cash & Short-Term Investments | 820.4m |
| Receivables | 94.5m |
| Other Current Assets | 148m |
| Non-Current Assets | 633.7m |
| Long-Term Investments | 289.1m |
| PP&E | 202.7m |
| Intangibles | 123.1m |
| Other Non-Current Assets | 18.9m |
| Current Liabilities | 134.1m |
| Accounts Payable | 35.1m |
| Accrued Liabilities | 66.6m |
| Other Current Liabilities | 32.4m |
| Non-Current Liabilities | 22.7m |
| Other Non-Current Liabilities | 22.7m |
Free Cash Flow Analysis
ABIOMED Inc
| USD | |
| Free Cash Flow | USD |
Earnings Waterfall
ABIOMED Inc
|
Revenue
|
1.1B
USD
|
|
Cost of Revenue
|
-200.6m
USD
|
|
Gross Profit
|
873.5m
USD
|
|
Operating Expenses
|
-619.4m
USD
|
|
Operating Income
|
254.1m
USD
|
|
Other Expenses
|
12.7m
USD
|
|
Net Income
|
266.8m
USD
|
0H7S Profitability Score
Profitability Due Diligence
ABIOMED Inc's profitability score is hidden . The higher the profitability score, the more profitable the company is.
Score
ABIOMED Inc's profitability score is hidden . The higher the profitability score, the more profitable the company is.
0H7S Solvency Score
Solvency Due Diligence
ABIOMED Inc's solvency score is hidden . The higher the solvency score, the more solvent the company is.
Score
ABIOMED Inc's solvency score is hidden . The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
0H7S Price Targets Summary
ABIOMED Inc
Dividends
Current shareholder yield for 0H7S is hidden .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?